Keros Therapeutics (KROS) Tops Q4 EPS by 22c
Tweet
Share
E-mailGet Alerts KROS Hot Sheet
Join SI Premium – FREE
Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($1.14), $0.22 better than the analyst estimate of ($1.36). Revenue for the quarter came in at $3.04 million versus the consensus estimate of $49.2 thousand.
For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FOMC minutes from July 28-29th meeting
- Uber launches autonomous rides in Zagreb via Pony.ai and Verne
- Analog Devices climbs as fiscal Q3 results, Q4 outlook beat forecasts
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
